Samsung Biologics PolyPeptide offer advances as shareholders elect new board
PolyPeptide shareholders backed all board proposals, electing five directors and voting to remove transfer and voting limits. Each step depends on the Samsung Peptide AG tender offer, and the release gives no price or timing.
What's new
PolyPeptide shareholders approved all board proposals on 26 October 2026, choosing five directors with John Chongbo Rim as chair and voting to remove transfer restrictions and voting limits from the articles.
Why it matters
PolyPeptide is a peptide CDMO with six GMP sites and GLP 1 exposure, and the votes clear governance steps for a takeover offer by a Samsung Biologics subsidiary.
What's next
The board changes take effect at settlement of the tender offer and the article changes once offer conditions are met or waived. The release gives no price, acceptance level or date.
BAAR, SWITZERLAND. Shareholders of PolyPeptide Group AG approved every board proposal at an extraordinary general meeting on 26 October 2026, clearing governance steps for the Samsung Biologics PolyPeptide offer, the company said. The vote installs a new five member board, but the elections take effect only when the tender offer settles. PolyPeptide makes peptide drug ingredients for other companies, including for GLP 1 medicines, and its shares trade on the SIX Swiss Exchange. The company release gave no offer price, acceptance level or settlement date.
Shareholders elect five directors in Baar
PolyPeptide said shareholders at the PolyPeptide extraordinary general meeting chose five new directors and named John Chongbo Rim as chair, according to a media release issued at 19:10 Central European time. The other four seats went to Seungho Ryu, Mihyun Yang, Joonkyung Seong and Cheol Woo Ryu. Both Ryus will also sit on the Remuneration and Nomination Committee. Each term ends at the close of the next annual general meeting, according to the release. PolyPeptide said shareholders backed all proposals put forward by the board, but it did not publish vote counts or the share of capital present. The release also did not say which current directors will leave or whether the new members were nominated by the bidder. Those details may appear in later filings.
Every election is conditional. The release states that the new board takes office only once Samsung Peptide AG settles its public tender offer, which covers every registered PolyPeptide share held by the public. Samsung Peptide AG is a wholly owned subsidiary of Samsung Biologics Co., Ltd., the company said. Until settlement, the vote sets out who will run the company if the deal closes, not who runs it today. Settlement is the point at which tendered shares are paid for and change hands. PolyPeptide did not say when it expects that to happen. It also did not report how many shareholders have tendered so far. The table below sets out the steps the release confirms and the condition attached to each one.
| Step | Date | What the release says | Condition |
|---|---|---|---|
| Offer prospectus published | 31 Aug 2026 | Samsung Peptide AG offer for all publicly held registered shares | Not stated in release |
| Extraordinary general meeting | 26 Oct 2026 | All board proposals approved | None |
| Five directors elected, Rim as chair | 26 Oct 2026 | Terms end at next annual general meeting | Settlement of the tender offer |
| Transfer and voting limits removed from articles | 26 Oct 2026 | Approved by shareholders | Offer conditions met or waived, except B.7.1(e) |
Transfer restrictions and voting limits to go
Shareholders also voted to delete the transfer restrictions, known in Swiss law as Vinkulierung, and the voting limitations, or Stimmrechtsbeschränkungen, from the articles of association, the release said. This change has its own trigger. It takes effect only if all conditions in the Samsung Peptide AG offer prospectus dated 31 August 2026 are met or waived, with one exception, the condition set out in section B.7.1(e) of that prospectus. The release does not describe what that condition covers. It does not give the current thresholds for share registration or voting either. Readers who want the exact wording can check the prospectus itself, which the release names but does not attach. The company did not explain why that single condition was carved out.
Until settlement, the vote sets out who will run the company if the deal closes, not who runs it today.
In general terms, clauses of this kind let a Swiss listed company refuse to register a holder above a set stake as a voting shareholder, or cap the votes any one holder can cast. A bidder seeking full control usually needs such limits removed so that it can register and vote all the shares it buys. That makes the article change a practical step for the Samsung Biologics PolyPeptide offer, not a separate deal. The EGM results release frames both resolutions as linked to the offer. It does not say whether the bidder has already crossed any ownership level or when any listing changes might follow.
Why a peptide CDMO draws a large buyer
PolyPeptide describes itself as a peptide CDMO, a contract development and manufacturing organization that makes peptide based active pharmaceutical ingredients for pharma and biotech customers. It says it works on projects from the earliest research stages through to commercial supply. The company traces its history to 1952 and says it runs six GMP certified facilities in Europe, the United States and India. GMP stands for good manufacturing practice, the quality standard regulators expect for drug production. PolyPeptide states that its portfolio has significant exposure to work on metabolic diseases, GLP 1 drugs among them. It does not name customers or products in the release. Its statement that it serves a fast growing market is the company's own view, not an independent market estimate.
Demand for GLP 1 peptide manufacturing gives that exposure weight. Eli Lilly said third quarter volume rose 53% while realized prices fell, as covered in our report on Lilly volume outrunning price cuts. Making peptide ingredients at scale is also exacting. Dr Reddy's halted semaglutide supply in July after an impurity showed up in scale up batches, as our story on the Dr Reddy's relaunch plan reported. Neither case involves PolyPeptide. They show why plant capacity and quality control are central to the peptide trade. The release does not say how Samsung Biologics plans to use PolyPeptide's sites, whether it will add capacity, or whether existing customer contracts will change after the deal.
What the release leaves out and what comes next
Several basic facts are missing from the release. It gives no offer price, no acceptance rate, no regulatory clearances obtained or pending, and no expected settlement date. It does not explain offer condition B.7.1(e), and it does not say whether PolyPeptide shares will be delisted after the deal. The release carries a standard warning that forward looking statements reflect management's current views and may differ from what actually happens. On the evidence of this document alone, the Samsung Biologics PolyPeptide offer has cleared a shareholder vote on governance, not completed. Readers should treat any claims about timing, synergies or future output as unconfirmed until the companies publish them. Peptide Zone will update this story when the offer settles or its terms change.
The next step is settlement of the tender offer by Samsung Peptide AG. At that point, according to the release, the five new directors take office and Rim becomes chair. The removal of the transfer restrictions and voting limits waits on a separate test, the meeting or waiving of the offer conditions other than B.7.1(e). The new board's terms then run to the next annual general meeting, where shareholders vote again. For patients, nothing in the release changes access to any approved peptide medicine, and no product or supply change was announced. Readers can follow further deals and plant news on the Industry desk, which tracks the business of making peptides at scale.
Conclusion
PolyPeptide shareholders approved all board proposals on 26 October 2026, electing five directors and voting to drop transfer and voting limits. Both steps hinge on the Samsung Biologics PolyPeptide offer by Samsung Peptide AG reaching settlement or meeting its conditions, the company said. The price, acceptance level and timing remain undisclosed in the release. The deal matters because PolyPeptide makes peptide ingredients, including for GLP 1 drugs, at six sites. What comes next depends on settlement.
